Tandem Diabetes Care (TNDM) Q3 2025: Pharmacy Channel Hits 5% of U.S. Sales, Unlocking Margin Upside
Tandem Diabetes Care’s Q3 showcased a pivotal shift as pharmacy channel sales reached 5% of U.S. revenue, signaling a new era for gross margin expansion and business model leverage. Strategic execution in pricing, direct international buildout, and product innovation is reshaping the company’s growth trajectory. Management’s confidence in sustaining double-digit growth is underpinned by a transformed commercial engine and a robust pipeline, though competitive and channel risks remain front of mind for 2026.
Summary
- Pharmacy Channel Momentum: Pharmacy benefit sales are scaling fast, driving margin and pricing leverage across the portfolio.
- Business Model Transformation: Direct European expansion and automation initiatives are set to structurally improve profitability.
- Growth Engine Reset: Product launches and channel mix shifts are positioned to reignite double-digit growth in 2026.
Performance Analysis
Tandem Diabetes Care delivered a record third quarter with $249 million in revenue, led by U.S. sales of $176 million and international sales of $74 million. The quarter’s outperformance was anchored by average selling price (ASP) increases in both pumps and supplies, particularly as the pharmacy channel scaled to 5% of U.S. sales. This marks a material shift in the revenue mix, as pharmacy access not only improves affordability and convenience for patients but also structurally enhances gross margin.
Gross margin expanded by three percentage points year-over-year to 54%, a direct result of price realization and favorable channel mix. Notably, Q3 marked a return to positive adjusted EBITDA and free cash flow, with $319 million in total cash and investments on the balance sheet. Operating expenses rose 4% year-over-year, primarily due to sales infrastructure investments and European expansion, but this was partially offset by a $5 million reduction in stock-based compensation and a $3 million restructuring charge aimed at ongoing cost discipline.
- Pricing Power Emerges: ASP increases contributed 5% to U.S. revenue growth, a trend that accelerated as pharmacy sales ramped.
- Renewals Anchor Predictability: More than 70% of U.S. sales are now recurring, driven by robust renewal rates and a 300,000+ installed base.
- International Direct Pivot: Direct sales in Europe are expected to lift ASPs by at least 30% over four years, setting up a step-change in profitability.
Pump shipments exceeded 20,000 in the U.S. and 9,000 internationally, with renewals comprising slightly more than half of total shipments. While new pump starts remain pressured, momentum is expected to return as new products and channel access take hold in 2026.
Executive Commentary
"Our substantial progress is starting to become evident in our financial results and serves as a testament to our strategic vision, hard work, and the collective dedication of our entire team. Establishing direct international operations is a critical step to strengthen our financial position by accelerating sales growth and driving margin expansion."
John Sheridan, President and Chief Executive Officer
"Our Q3 gross margin of 54% increased approximately 3 percentage points year over year and increased approximately 2 percentage points compared to Q2. The combination of price, channel benefit, and scaling reductions in MOBI costs underpin both our near and long-term gross margin goals."
Lee Vossler, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Pharmacy Channel Acceleration
Pharmacy benefit, a reimbursement pathway where patients access devices and supplies through retail pharmacies rather than traditional durable medical equipment (DME) channels, is now 5% of U.S. sales, up from near zero a year ago. This transition is delivering higher ASPs and improved gross margins, while also simplifying patient access and reducing administrative burden. Tandem’s contracts with all major pharmacy benefit managers (PBMs) position the company to further expand coverage and volume, with 40% of U.S. lives now covered for Mobi. Early customer uptake is strong, and management expects this channel to become a major growth and margin lever in 2026 and beyond.
2. Direct International Expansion
Direct sales, where Tandem sells directly rather than through distributors, will launch in the UK, Switzerland, and Austria in early 2026, with other countries to follow. This move is expected to raise average selling prices by at least 30% over the four-year life of a patient, compared to current distributor pricing. The transition is supported by new local hires, many of whom already sell Tandem products, smoothing the operational shift. Management expects direct sales to account for nearly 15% of international revenue in 2026, up from less than 5% this year.
3. Innovation Pipeline and Portfolio Expansion
Tandem is doubling down on product innovation, with Mobi Tubeless (an extended-wear patch pump) prioritized ahead of SteadySet, reflecting strong market enthusiasm for tubeless, seven-day wear options. The integration of Abbott’s Freestyle Libre 3 Plus sensor with T-Slim X2 and the expansion of the T-Slim mobile app internationally are also broadening the company’s competitive moat. The pipeline includes a fully closed-loop system in partnership with UVA, with pivotal trials planned for next year, aiming to further differentiate Tandem’s automated insulin delivery (AID) platforms.
4. Type 2 Diabetes Market Development
Tandem has moved from pilot to full commercial promotion of Control IQ+ for people with Type 2 diabetes, a population that could double the company’s U.S. addressable market. Early data from pilot territories shows the highest productivity in bringing new technology to this segment, and positive feedback from both patients and physicians is supporting broader rollout. Management views Type 2 as a long-term growth engine, especially as pharmacy and tubeless options become more widely available.
5. Operational Efficiency and Restructuring
Restructuring and automation initiatives are underway to streamline operations and support scalable growth. Recent actions include a $3 million restructuring charge and a $5 million reduction in stock-based compensation, with further leverage expected as pharmacy and direct international channels scale. These cost actions are designed to underpin sustained margin expansion as the revenue mix evolves.
Key Considerations
This quarter marks a structural inflection in Tandem’s revenue and margin model, with pharmacy channel access and direct international sales setting the stage for sustained growth and profitability improvement. Investors should weigh the durability of these trends against competitive and channel risks.
Key Considerations:
- Channel Mix Shift: Pharmacy benefit sales are expanding rapidly, but long-term pricing pressure remains a risk as more competitors enter the channel.
- Renewal-Driven Recurring Revenue: Over 70% of U.S. sales are now recurring, providing greater visibility and stability, but new customer growth must accelerate to sustain long-term expansion.
- Direct Model Upside: Direct sales in Europe are expected to meaningfully lift ASPs and margins, but execution risk exists during the distributor-to-direct transition.
- Innovation Timelines: The pace of regulatory approvals (e.g., Mobi Tubeless, Android app) and successful product launches will determine competitive positioning in 2026.
- Type 2 Market Penetration: Full-scale Type 2 launch is underway, but market development and patient education will be essential to unlock this large opportunity.
Risks
Competitive rebidding in the pharmacy channel could erode pricing power over time, especially as other pump makers ramp their presence. The transition to direct sales in Europe carries operational and inventory risks, including potential distributor destocking and inventory buybacks. Execution of product launches and regulatory approvals (e.g., Mobi Tubeless, fully closed-loop algorithm) are critical to maintaining momentum. Management acknowledges these risks but believes the current trajectory is favorable given early progress and channel leverage.
Forward Outlook
For Q4 2025, Tandem expects:
- Record gross margins in the mid to high 50% range, driven by pharmacy channel mix and supply pricing.
- U.S. pump shipments to follow a seasonal curve, with nearly 30% of full-year shipments expected in Q4.
For full-year 2025, management reaffirmed:
- Worldwide sales approaching $1 billion, with U.S. revenue of $700 million and international revenue of $300 million.
- Gross margin guidance of 53% to 54%.
- Adjusted EBITDA guidance at negative 5% of sales, reflecting earlier in-process R&D charges.
Looking to 2026, management highlighted:
- Return to new pump growth driven by MDI conversions and expanded pharmacy access.
- Direct international sales to reach 15% of OUS revenue, lifting ASPs by at least 30% over patient lifecycles.
- Gross margin target of at least 60% by Q4 2026, with continued adjusted EBITDA and free cash flow improvement.
Takeaways
Tandem is executing a multi-pronged transformation, with pharmacy channel expansion and direct international sales as key levers for growth and profitability. Investors should monitor the pace of new product launches, the sustainability of pricing power, and the operational execution of the direct model pivot.
- Pharmacy Channel Is a Structural Lever: Early traction in pharmacy sales is already driving higher ASPs and margin, with significant runway ahead as coverage expands.
- Direct Sales Model in Europe Will Be a Margin Catalyst: The shift to direct operations is expected to deliver step-change ASP and margin gains, but execution through the transition period will be critical.
- 2026 Hinges on Innovation and Channel Execution: Mobi Tubeless, Type 2 market expansion, and pharmacy channel scale are the major growth engines to watch in the coming year.
Conclusion
Tandem Diabetes Care’s Q3 results confirm a business model in active transformation, with pharmacy and direct international channels unlocking new profit pools. The company’s ability to execute on product launches, channel expansion, and operational efficiency will define its growth and margin trajectory as it enters 2026.
Industry Read-Through
Tandem’s rapid pharmacy channel adoption signals a broader industry shift toward retail pharmacy reimbursement for diabetes devices, with implications for pricing, patient access, and competitive dynamics across the sector. The move to direct sales in Europe is likely to be emulated by other medtech firms seeking to capture higher margins and closer relationships with patients and providers. Innovation cycles in automated insulin delivery and closed-loop systems remain critical, as market leaders race to differentiate on ease of use, integration, and outcomes. Investors should watch for pharmacy channel penetration, direct sales transitions, and product innovation as key themes shaping the diabetes technology landscape in 2026 and beyond.